Written by: Dr. Akash Chandawarkar, Board Certified Plastic Surgeon, Mirror Plastic Surgery | Last updated: September 9, 2026
Key Takeaways
- GLP-1 therapy delivers clinically proven weight loss of 15–20% or more of body weight, with strong cardiovascular and renal benefits.1
- Anti-aging effects are indirect, with better systemic health but only limited impact on skin aging and facial appearance.1
- “Ozempic face” and muscle loss are real risks.1 Gradual weight loss, high protein intake, and resistance training help protect facial volume and lean mass.
- Weight regain is common after stopping GLP-1s, so long-term maintenance planning and medical supervision matter for lasting results.1
- At Mirror Plastic Surgery, Dr. Chandawarkar designs personalized GLP-1 protocols that support both your weight-loss results and your appearance. Schedule your consultation to learn how GLP-1 therapy can fit your health goals.
What GLP-1 Therapy Is And How It Works
Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted by intestinal L-cells in response to food. GLP-1 receptor agonists are synthetic analogs engineered to activate the GLP-1 receptor at concentrations far above normal post-meal levels. They stimulate insulin only when glucose is already elevated, suppress glucagon, slow gastric emptying, and curb appetite through hypothalamic signaling.
Common brand names include semaglutide (Wegovy for obesity, Ozempic for diabetes) and tirzepatide (Zepbound and Mounjaro), with tirzepatide acting as a dual GIP/GLP-1 agonist. Both are FDA-approved for chronic weight management and type 2 diabetes. In a clinical setting, “GLP-1 peptide therapy” may also describe newer compounded formulations such as GLP-3R, available at Mirror Plastic Surgery, which are reported to cause fewer gastrointestinal side effects and less muscle wasting than older agents.
What GLP-1 Therapy Can Do For Weight And Health
The clinical trial data for GLP-1 medications in weight loss is among the strongest in obesity medicine:
- In the STEP 1 trial (Wilding et al. 2021, NEJM), adults with obesity on semaglutide 2.4 mg weekly achieved a mean weight loss of 14.9% over 68 weeks, versus 2.4% on placebo, with 69% losing 10% or more.1
- In the SURMOUNT-1 trial (Jastreboff et al. 2022, NEJM), tirzepatide 15 mg produced a mean weight loss of 20.9% at 72 weeks, with 50.1% of participants losing at least 20%.1
- In the SURMOUNT-5 head-to-head trial (Aronne et al., NEJM 2025), tirzepatide produced 20.2% mean weight loss versus 13.7% with semaglutide over 72 weeks, a statistically significant advantage of about 6.5 percentage points.1
- The SELECT trial (Lincoff et al. 2023) found that semaglutide reduced major adverse cardiovascular events by 20% in patients with obesity and established cardiovascular disease.1
- The FLOW trial of semaglutide in chronic kidney disease was stopped early for efficacy, reporting a significant reduction in kidney-disease progression and cardiovascular and renal death.1
These benefits are well-established and FDA-recognized. They form the scientific foundation for GLP-1 therapy and differ from the more speculative anti-aging claims that circulate online.
How GLP-1 Therapy Relates To Anti-Aging
GLP-1 therapy improves systemic health markers that support healthy aging, yet its effect on skin aging is indirect at best. Rapid weight loss can reduce facial volume, which people often describe as “Ozempic face.” Ongoing research explores potential neuroprotective and anti-inflammatory effects that may slow age-related decline, but human evidence for lifespan extension remains unproven.
A 2026 narrative review in the Journal of Clinical Medicine (Bijoch) explicitly concludes that evidence for slowing biological aging itself remains unproven; observed benefits are strongest for disease risk and body composition, not for aging as a primary endpoint. Mechanistic and preclinical data suggest plausible pathways such as reduced oxidative stress, improved mitochondrial function, attenuated low-grade inflammation (“inflammaging”), and modulation of cellular senescence. These findings have not yet translated into demonstrated lifespan benefits in humans.
GLP-1 receptors are expressed in skin and dermal fibroblasts, and preclinical work suggests GLP-1 signaling can modulate fibroblast activity, collagen metabolism, inflammation, and wound healing, but direct dermatological effects in humans are largely unstudied. Commercial enthusiasm around “longevity” currently outpaces the evidence base.
The “Ozempic Face” Phenomenon And How To Reduce It
One aesthetic consequence of rapid weight loss that does have clear evidence is facial volume loss, often called “Ozempic face.” With weight loss of roughly 15–22% of body weight, facial fat compartments deflate faster than the overlying skin can contract.1 This process produces laxity, deepened nasolabial folds, jowling, and temporal and cheek hollowing, particularly in older patients.
This pattern is not unique to GLP-1 medications. Any rapid, substantial weight loss can create similar facial changes. GLP-1 therapy stands out because it makes this degree of weight loss more achievable and often faster than older interventions.
A retrospective imaging study from Vanderbilt University Medical Center found a median 9% decrease in total midfacial volume, with roughly 7% of midface volume lost per 10 kg of total weight loss.1 Superficial fat compartments, which sit closest to the skin surface, were most affected and declined by a median of 11%.
A quantitative 3D imaging study found that patients on semaglutide experienced average reductions of 41.8% in temporal fat pads and 69.9% in cheek fat pads, far exceeding the approximately 9.2% reduction in total body fat.1 These findings suggest that GLP-1 agents may preferentially target facial adipose depots.
Practical strategies to reduce this risk include:
- Aiming for gradual weight loss rather than maximum speed, since slower titration reduces the rate of facial deflation
- Prioritizing adequate protein intake (1.2–1.6 g/kg body weight daily) to support lean tissue
- Engaging in resistance training to preserve lean mass throughout the face and body
- Considering cosmetic options such as dermal fillers or collagen-stimulating peptides (for example, GHK-CU) once weight has stabilized, always under physician supervision
At Mirror Plastic Surgery, Dr. Chandawarkar’s dual expertise in metabolic health and aesthetic outcomes keeps these conversations proactive, before facial changes become a concern.
Talk to our team about a weight-loss plan that protects your facial appearance.
Muscle Loss On GLP-1 Therapy And How To Protect Lean Mass
Muscle loss is a real concern with GLP-1 therapy and deserves early planning. A 2026 narrative review by researchers at UC San Diego synthesizing 21 human studies found that muscle loss accounted for up to 8.5% to 24.5% of total weight lost during GLP-1 receptor agonist therapy.1 A meta-analysis cited in the same review found that, on average, roughly 28% of total weight loss was attributable to muscle-based indices.1
These changes can be largely mitigated with adequate protein intake (1.2–1.6 g/kg daily), resistance training two to three times per week, and physician-supervised protocols that may include muscle-preserving peptides. The concern grows for adults over 60.
Eric Ravussin, PhD, director of the Pennington-Louisiana Nutrition Obesity Research Center, noted that loss of bone and muscle mass naturally accelerates after age 40, and past age 60 adipogenesis increases while bone resorption surpasses bone formation. Starting GLP-1 therapy at that point may compound the risk of excessive muscle loss and contribute to osteoporosis, frailty, and fractures.
Actionable strategies for muscle preservation on GLP-1 therapy include:
- Pairing adequate protein intake of 1.2–1.6 grams per kilogram of body weight daily, spread across meals, with resistance training two to three times per week using compound movements and progressive overload
- Monitoring body composition with bioelectrical impedance analysis (BIA) or DEXA every three to six months
- Discussing adjunctive therapies with your physician, since growth hormone-releasing peptides such as sermorelin and ipamorelin, available at Mirror Plastic Surgery, may support muscle preservation alongside GLP-1 therapy
Dr. Chandawarkar designs protocols that address muscle preservation from the outset and incorporates lab-based body composition monitoring and adjunctive peptide options where clinically appropriate.
Planning For Long-Term GLP-1 Use And Maintenance
Even with the right muscle-preservation plan, many patients worry about what happens when they stop GLP-1 therapy. For most people, some form of ongoing GLP-1 treatment is necessary to maintain results. In the STEP 1 trial extension, patients who discontinued semaglutide regained about two-thirds of their lost weight within one year. Obesity behaves as a chronic condition, and GLP-1s work only while you take them.
Discontinuation rates for GLP-1 receptor agonist medications are high, varying between 20% and over 50%, with only 48.6% of continuing patients achieving adequate adherence at one year. Common reasons include gastrointestinal side effects, cost, plateau, and concerns about long-term safety. Older adults face added vulnerability because rapid weight reduction can accelerate muscle loss and impair mobility.
The 2026 TOS–OMA–OAC Expert Guidance Statement strongly recommends continued obesity medication for patients in the weight maintenance phase. The authors frame pharmacotherapy as lifelong once initiated, similar to treatment for hypertension or diabetes. Reduced-dose and extended-interval maintenance strategies appear in practice, although the evidence base for these approaches remains thinner than for standard continuous dosing.
A sustainable plan includes lifestyle changes, body composition monitoring, and, when appropriate, a transition to newer agents with fewer side effects. Mirror Plastic Surgery’s concierge model supports this kind of long-term, evolving care.
Choosing Between Semaglutide, Tirzepatide, And Newer Options
The semaglutide versus tirzepatide comparison now has definitive head-to-head data. Key distinctions include:
- Semaglutide (Wegovy): About 14.9% average weight loss at 68 weeks in STEP 1; single GLP-1 receptor agonist
- Tirzepatide (Zepbound): About 20.9% average weight loss at 72 weeks in SURMOUNT-1; dual GIP/GLP-1 agonist
- Head-to-head advantage: SURMOUNT-5 showed tirzepatide’s advantage of approximately 6.5 percentage points over semaglutide
Mirror Plastic Surgery also offers GLP-3R compounding, a newer-generation formulation under study for potential advantages such as fewer gastrointestinal side effects and less muscle wasting. The right choice depends on your health profile, metabolic markers, and goals, which calls for physician-level evaluation rather than a generic telehealth questionnaire.
Summary Of GLP-1 Benefits And Risks
- GLP-1 therapy produces significant weight loss, with exact results depending on the specific medication and dose.
- Cardiovascular and renal benefits are well-established and recognized by the FDA.
- Anti-aging effects relate mainly to improved metabolic health, while direct effects on skin aging remain limited.
- Facial volume loss and muscle loss are meaningful aesthetic and functional risks that respond to thoughtful dosing, protein intake, and resistance training.
- Weight regain often follows abrupt discontinuation, so long-term maintenance planning matters.
- Medical supervision with lab-based, personalized protocols supports both safety and appearance.
Frequently Asked Questions
Does GLP-1 Help With Anti-Aging?
As discussed earlier, GLP-1 medications improve systemic health but do not directly reverse skin aging. The main aesthetic risk involves facial volume loss from rapid weight loss. Neuroprotective and anti-inflammatory effects remain under study, and human lifespan extension has not been demonstrated.
Do GLP-1s Deplete Collagen?
The evidence remains mixed. Some research suggests GLP-1s may reduce advanced glycation end-products and support collagen homeostasis, while other findings indicate that rapid weight loss and reduced nutrient intake can impair collagen production. The visible skin aging seen with GLP-1 use primarily reflects facial fat loss rather than direct collagen depletion. Preclinical work shows GLP-1 signaling can modulate fibroblast activity and collagen metabolism, but direct dermatological effects in humans remain largely unstudied.
Why Are Older People Quitting GLP-1?
Common reasons include gastrointestinal side effects, cost, fear of muscle loss, and concerns about long-term safety. Older adults are particularly vulnerable to muscle loss during rapid weight reduction, which can affect mobility and independence. Some patients also experience facial changes they find distressing. Discontinuation rates across the drug class range from 20% to over 50% within one year, which highlights the need for proactive management and ongoing physician support.
What I Wish I Knew Before Starting GLP-1
Many patients wish they had known that GLP-1s require a long-term commitment, that muscle loss requires active prevention through protein intake and resistance training, and that facial volume loss can occur with rapid weight loss. The medications work only while you take them, and stopping typically leads to significant weight regain within a year. Working with a physician who addresses these concerns proactively, monitors body composition, and adjusts the protocol over time can improve both outcomes and experience.
How To Prevent Muscle Loss On GLP-1
As detailed in the muscle loss section, prioritize protein intake of 1.2–1.6 g/kg of body weight daily and resistance training two to three times per week to preserve lean mass. Partner with your physician to monitor body composition using BIA or DEXA every three to six months. Some patients benefit from adjunctive therapies such as growth hormone-releasing peptides like sermorelin and ipamorelin. Slower dose titration and avoiding maximum-speed weight loss also reduce the proportion of weight lost from muscle.
Are GLP-1s Safe For Long-Term Use?
Current evidence supports a strong safety profile for long-term use, with the most common side effects being gastrointestinal and typically transient. Long-term data continues to accumulate, and medical supervision is essential to monitor for rare complications and to manage muscle and bone preservation, particularly in adults over 60. Expert guidance from major obesity societies now frames GLP-1 pharmacotherapy as a lifelong intervention for most patients, similar to treatment for hypertension or diabetes.
Can I Take GLP-1s With Other Peptides?
Combination therapy can be appropriate under physician supervision. Some practices pair GLP-1 therapy with collagen-stimulating peptides like GHK-CU or muscle-preserving peptides like sermorelin and ipamorelin to address aesthetic and body composition concerns alongside weight loss. Mirror Plastic Surgery offers this kind of integrated, lab-based approach. Always consult a board-certified physician before combining therapies, because interactions and contraindications depend on individual health status.
The Doctor’s Bottom Line
GLP-1 therapy is a powerful, evidence-based tool for weight loss with meaningful systemic health benefits. Its anti-aging effects are real but indirect, and without proper medical supervision, rapid weight loss can accelerate facial aging and erode the muscle mass that supports long-term health and function. The gap between what GLP-1s can do and what the wellness industry claims they do remains significant, so you benefit from a physician who understands both metabolic medicine and aesthetic outcomes.
From inflammation and autoimmune conditions to weight management and anti-aging, Mirror Plastic Surgery offers advanced peptide therapies that address a wide range of health and wellness concerns. Every protocol is designed around your labs and physiology, supervised by Dr. Akash Chandawarkar personally, and supported with concierge-level care throughout your journey.
Request a consultation to design a peptide protocol tailored to your labs and goals.
Medical Disclaimer
This article is for educational purposes only and does not replace medical advice. Peptide therapies are not FDA-regulated for all uses, and results vary. Always consult a board-certified physician to determine whether a treatment is right for you.
1 Results may vary from person to person. Editorial content, before and after images, and patient testimonials do not constitute a guarantee of specific results.
Peptide therapy is intended for wellness and optimization purposes and is not prescribed to diagnose, treat, cure, or prevent disease unless specifically stated. Many peptides are not FDA-approved and may be used off-label. Some have limited long-term safety data, with a potential for unknown risks, complications, or desensitization with prolonged use.
